A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RELEVANCE
- Sponsors Celgene Corporation
- 25 Jan 2018 According to a Celgene Corporation media release, the full data set will be presented at a future medical congress.
- 21 Dec 2017 Results published in a Celgene Corporation media release.
- 31 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Jun 2024.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History